EcoDrugPlus

Ribosomal Protein Lateral Stalk Subunit P0

Ensembl ID : ENSAOCG00000003922
Gene Symbol: RPLP0
3 Cross references
403 Possible Orthologues:

Ribosomal Protein Lateral Stalk Subunit P1

Ensembl ID : ENSAOCG00000009145
Gene Symbol: RPLP1
3 Cross references
386 Possible Orthologues:

Selectin E

Ensembl ID : ENSAOCG00000007401
Gene Symbol: SELE
4 Cross references
181 Possible Orthologues:

Serine/threonine-Protein Kinase A-Raf-Like

Ensembl ID : ENSAOCG00000019053
Gene Symbol: LOC111568015
3 Cross references
191 Possible Orthologues:

Serine/threonine-Protein Kinase Pim-1-Like

Ensembl ID : ENSAOCG00000019060
Gene Symbol: LOC111565154
3 Cross references
250 Possible Orthologues:

Serpin Family C Member 1

Ensembl ID : ENSAOCG00000000887
Gene Symbol: SERPINC1
3 Cross references
202 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSAOCG00000004133
Gene Symbol: LOC111573147
2 Cross references
385 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSAOCG00000004111
Gene Symbol: LOC111573138
2 Cross references
352 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSAOCG00000004128
Gene Symbol: LOC111573151
2 Cross references
385 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSAOCG00000016988
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
319 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSAOCG00000022955
Gene Symbol: SIGMAR1
3 Cross references
205 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSAOCG00000000167
Gene Symbol: SIRT1
3 Cross references
158 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).